- WKN: KSAG88
- ISIN: DE000KSAG888
- Land: Deutschland
Nachricht vom 25.11.2021 | 21:57
K+S Aktiengesellschaft: Final FREP findings do not result in adjustments to valuations
K+S Aktiengesellschaft / Key word(s): Miscellaneous
The German Financial Reporting Enforcement Panel e.V. (FREP - "DPR") has today issued its final examination findings to K+S Aktiengesellschaft ("K+S") in the procedure for the examination of the consolidated financial statements of K+S as of December 31, 2019, including the associated Group management report, as well as the abbreviated consolidated financial statements as of June 30, 2020, including the associated interim management report.
According to K+S, the final findings do not result in any adjustment requirements for the valuations of the Potash and Magnesium Products cash-generating unit ("CGU Potash") in the respective financial statements. The preliminary findings regarding the consolidated financial statements as of December 31, 2019, that the value in use of the CGU Potash had not been reliably determined and was significantly overstated, and therefore that recoverability had not been demonstrated, are no longer included in the final DPR findings. The preliminary DPR finding regarding the abbreviated consolidated financial statements as of June 30, 2020, that the recoverability of the net assets of the CGU Potash had not been demonstrated, are also no longer included in the final findings.
With respect to the consolidated financial statements as of December 31, 2019, the DPR's findings are as follows:
In the consolidated financial statements of K+S AG as of December 31, 2019, material assumptions, changes in assumptions, discretionary decisions and uncertainties in estimates in connection with the impairment test of the Potash and Magnesium Products cash-generating unit (CGU Potash) were not reported appropriately.
The net assets of the CGU Potash in the amount of 5,428.3 million euros (51.3% of the consolidated balance sheet total) mainly consist of tangible fixed assets of the Bethune potash plant in Canada. In particular, it was not disclosed that for this plant, for the first time, not only the reported reserves but also 40% of resources were used in determining the value in use, which - unlike reserves - have not yet been proven with sufficient certainty or are not yet economically recoverable at the time under consideration. Furthermore, no reference was made to the extension of the operating life used as a basis for this plant, which more than doubled to approx. 150 years (perpetuity) as a result of the consideration of resources. Instead, the statement in the notes to the consolidated financial statements that the operating lives of the CGUs are determined by the raw material reserves does not indicate that resources have been considered. The future expansion of the maximum production capacity in Bethune from 2.86 mt/a to 4.0 mt/a, which was assumed for the first time in the impairment test, was also not reported. In this way, the comparability required of IFRS financial statements in accordance with IAS 1.1 is not established.
There is a breach of IAS 1.122 and IAS 1.125, according to which the discretionary decisions associated with the accounting methods applied, as well as significant assumptions and estimation uncertainties, must be disclosed in the notes to the consolidated financial statements. In addition, IAS 1.31 in conjunction with IAS 36.132 also require an entity to consider additional disclosures if the effects of events and conditions on the financial position would otherwise not be understandable to the readers of the financial statements.
With regard to the abbreviated consolidated financial statements as of June 30, 2020, the DPR's findings are:
K+S has been requested by the DPR to indicate whether the Company agrees or disagrees with the findings by December 9, 2021. By agreeing, the proceedings would be terminated.
Julia Bock, CFA
Phone: +49 561 9301-1009
|Phone:||+49 561 9301 0|
|Fax:||+49 561 9301 2425|
|Listed:||Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Hanover, Munich, Stuttgart; Regulated Unofficial Market in Tradegate Exchange|
|EQS News ID:||1252098|
|End of Announcement||DGAP News Service|
K+S Aktiengesellschaft: German Federal Cartel ...
K+S Aktiengesellschaft: Final FREP findings do ...
K+S Aktiengesellschaft: Preliminary announceme ...
K+S Aktiengesellschaft: Preliminary examinatio ...
K+S Aktiengesellschaft: K+S raises operating f ...
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
03. Dezember 16:37 Allianz: Kursziel 250 Euro
03. Dezember 16:48 Update DocuSign: Minus steigt auf 40 Prozent! Der nächste ...
03. Dezember 17:00 DAX: Der nächste Nackenschlag
03. Dezember 17:54 Börsenpunk: DAX - Angst ist zurück an den Märkten - jetzt trotzdem ...
03. Dezember 18:09 Alibaba, Tencent und Co: Kleiner Crash vorm Wochenende
News im Fokus
Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an
03. Dezember 2021, 07:03
FY 2020/2021 Financial Results
16. Dezember 2021
Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen
02. Dezember 2021